EA026213B1 - Термостабильная твердая фармацевтическая композиция, содержащая наномицеллы, и способ ее получения - Google Patents

Термостабильная твердая фармацевтическая композиция, содержащая наномицеллы, и способ ее получения Download PDF

Info

Publication number
EA026213B1
EA026213B1 EA200900572A EA200900572A EA026213B1 EA 026213 B1 EA026213 B1 EA 026213B1 EA 200900572 A EA200900572 A EA 200900572A EA 200900572 A EA200900572 A EA 200900572A EA 026213 B1 EA026213 B1 EA 026213B1
Authority
EA
Eurasian Patent Office
Prior art keywords
micelles
pharmaceutical composition
mixture
peg
solid pharmaceutical
Prior art date
Application number
EA200900572A
Other languages
English (en)
Russian (ru)
Other versions
EA200900572A1 (ru
Inventor
Ян П. Мешвитцер
Original Assignee
Солвей Фармасьютикалс Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Солвей Фармасьютикалс Б.В. filed Critical Солвей Фармасьютикалс Б.В.
Publication of EA200900572A1 publication Critical patent/EA200900572A1/ru
Publication of EA026213B1 publication Critical patent/EA026213B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
EA200900572A 2006-10-20 2007-10-19 Термостабильная твердая фармацевтическая композиция, содержащая наномицеллы, и способ ее получения EA026213B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85302306P 2006-10-20 2006-10-20
EP06122648 2006-10-20
PCT/EP2007/061194 WO2008046905A1 (en) 2006-10-20 2007-10-19 Micellar nanoparticles of chemical substances

Publications (2)

Publication Number Publication Date
EA200900572A1 EA200900572A1 (ru) 2009-10-30
EA026213B1 true EA026213B1 (ru) 2017-03-31

Family

ID=38661928

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200900572A EA026213B1 (ru) 2006-10-20 2007-10-19 Термостабильная твердая фармацевтическая композиция, содержащая наномицеллы, и способ ее получения

Country Status (9)

Country Link
EP (1) EP2083799A1 (de)
JP (1) JP5439182B2 (de)
KR (1) KR101434334B1 (de)
AU (1) AU2007312233B2 (de)
CA (1) CA2666587C (de)
EA (1) EA026213B1 (de)
IL (1) IL197701A (de)
NO (1) NO20091975L (de)
WO (1) WO2008046905A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR071375A1 (es) * 2008-04-22 2010-06-16 Solvay Pharm Gmbh Formulaciones para ingredientes farmaceuticos activos de permeabilidad deficiente, proceso de preparacion y producto
RU2519193C2 (ru) 2008-09-12 2014-06-10 Критикал Фармасьютикалс Лимитед Усовершенствование всасывания терапевтических средств через слизистые оболочки или кожу
AR075180A1 (es) * 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
EP2841090A1 (de) * 2012-04-24 2015-03-04 Amylin Pharmaceuticals, LLC Stellenspezifische enzymatische modifizierung von exendinen und analoga davon
GB201304662D0 (en) 2013-03-14 2013-05-01 Sigmoid Pharma Ltd Compositions
FR3014317B1 (fr) * 2013-12-11 2016-04-22 Patrice Binay Nouveau procede de fabrication de formulations pharmaceutiques transmuqueuses et formations ainsi obtenues
EP3424493A1 (de) * 2017-07-07 2019-01-09 SolMic Research GmbH Stabile cannabinoide zusammensetzungen
WO2020107119A1 (en) * 2018-11-30 2020-06-04 Canopy Growth Corporation Compositions comprising a cannabinoid or a cannabis-derived compound, methods of making and use
EP4005561A4 (de) * 2019-07-25 2022-12-07 Beijing Shenogen Pharma Group Ltd. Nanomicellenherstellung von icaritin und verfahren zu ihrer herstellung und verwendung davon
CN112915121A (zh) 2019-12-06 2021-06-08 汉义生物科技（北京）有限公司 一种大麻素纳米胶束制剂及其制备方法
JP2023504756A (ja) 2019-12-09 2023-02-06 ニコベンチャーズ トレーディング リミテッド カンナビノイドを含む口腔用製品
WO2023002199A1 (en) * 2021-07-22 2023-01-26 Nicoventures Trading Limited Composition comprising a constituent, derivative or extract of cannabis
WO2023002196A1 (en) * 2021-07-22 2023-01-26 Nicoventures Trading Limited Constituent, derivative or extract of cannabis in a water soluble matrix
IL309989A (en) * 2021-07-22 2024-03-01 Nicoventures Trading Ltd Compounds that include components, derivatives or extracts of cannabis
IL310125A (en) * 2021-07-22 2024-03-01 Nicoventures Trading Ltd Compositions comprising an ingredient, derivative or extract of cannabis

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281420A (en) * 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
WO2001012155A1 (en) * 1999-08-17 2001-02-22 Lipocine, Inc. Compositions and methods for enhanced absorption of hydrophilic therapeutic agents
WO2001058450A2 (fr) * 2000-02-09 2001-08-16 Sanofi-Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
WO2003026647A1 (en) * 2001-09-21 2003-04-03 Solvay Pharmaceuticals B.V. Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
WO2003026648A1 (en) * 2001-09-21 2003-04-03 Solvay Pharmaceuticals B.V. 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity
WO2005041929A1 (en) * 2003-11-03 2005-05-12 Lipocine, Inc Pharmaceutical compositions with synchronized solubilizer release
WO2005053727A2 (en) * 2003-11-29 2005-06-16 Sangstat Medical Corporation Pharmaceutical compositions for bioactive peptide agents
WO2005063206A1 (en) * 2003-12-23 2005-07-14 Alza Corporation Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
US20060074027A1 (en) * 2004-02-10 2006-04-06 Takeda Pharmaceutical Company Limited Sustained-release preparations
WO2006045799A2 (en) * 2004-10-25 2006-05-04 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising cb1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type i, obesity and related conditions
WO2006113631A2 (en) * 2005-04-18 2006-10-26 Rubicon Research Pvt. Ltd. Bioenhanced compositions
WO2006135480A2 (en) * 2005-04-08 2006-12-21 Abbott Laboratories Oral pharmaceutical formulations comprising fenofibric acid and/or its salts

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0305941D0 (en) * 2003-03-14 2003-04-23 Camurus Ab Composition
CA2537029C (en) * 2003-11-26 2013-03-12 Likan Liang Micellar systems useful for delivery of lipophilic or hydrophobic compounds

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281420A (en) * 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
WO2001012155A1 (en) * 1999-08-17 2001-02-22 Lipocine, Inc. Compositions and methods for enhanced absorption of hydrophilic therapeutic agents
WO2001058450A2 (fr) * 2000-02-09 2001-08-16 Sanofi-Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
WO2003026647A1 (en) * 2001-09-21 2003-04-03 Solvay Pharmaceuticals B.V. Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
WO2003026648A1 (en) * 2001-09-21 2003-04-03 Solvay Pharmaceuticals B.V. 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity
WO2005041929A1 (en) * 2003-11-03 2005-05-12 Lipocine, Inc Pharmaceutical compositions with synchronized solubilizer release
WO2005053727A2 (en) * 2003-11-29 2005-06-16 Sangstat Medical Corporation Pharmaceutical compositions for bioactive peptide agents
WO2005063206A1 (en) * 2003-12-23 2005-07-14 Alza Corporation Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
US20060074027A1 (en) * 2004-02-10 2006-04-06 Takeda Pharmaceutical Company Limited Sustained-release preparations
WO2006045799A2 (en) * 2004-10-25 2006-05-04 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising cb1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type i, obesity and related conditions
US20060128673A1 (en) * 2004-10-25 2006-06-15 Michael Firnges Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of obesity and related conditions
WO2006135480A2 (en) * 2005-04-08 2006-12-21 Abbott Laboratories Oral pharmaceutical formulations comprising fenofibric acid and/or its salts
WO2006113631A2 (en) * 2005-04-18 2006-10-26 Rubicon Research Pvt. Ltd. Bioenhanced compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VERVAET C, REMON J P: "Continuous granulation in the pharmaceutical industry", CHEMICAL ENGINEERING SCIENCE, OXFORD, GB, vol. 60, 1 January 2005 (2005-01-01), GB, pages 3949 - 3957, XP002458753, ISSN: 0009-2509, DOI: 10.1016/j.ces.2005.02.028 *

Also Published As

Publication number Publication date
NO20091975L (no) 2009-07-09
KR101434334B1 (ko) 2014-08-28
JP2010506886A (ja) 2010-03-04
IL197701A0 (en) 2009-12-24
EA200900572A1 (ru) 2009-10-30
JP5439182B2 (ja) 2014-03-12
CA2666587C (en) 2015-12-22
IL197701A (en) 2014-12-31
AU2007312233A1 (en) 2008-04-24
WO2008046905A1 (en) 2008-04-24
KR20090077074A (ko) 2009-07-14
EP2083799A1 (de) 2009-08-05
AU2007312233B2 (en) 2012-09-20
CA2666587A1 (en) 2008-04-24

Similar Documents

Publication Publication Date Title
EA026213B1 (ru) Термостабильная твердая фармацевтическая композиция, содержащая наномицеллы, и способ ее получения
US7923026B2 (en) Embedded micellar nanoparticles
US20190275019A1 (en) Pharmaceutical compositions
JP5936705B2 (ja) 高融点疎水性化合物のバイオアベイラビリティが向上した薬学的組成物
RU2489149C2 (ru) Стабилизированные аморфные формы иматиниба мезилата
KR20100017109A (ko) 지프라시돈 제제
EP3254699B1 (de) Feste dispersion mit dutasterid und zusammensetzung damit
TWI392507B (zh) 包埋的膠束奈米顆粒
EP3250188B1 (de) Pharmazeutische zusammensetzung mit aprepitant und verfahren zur herstellung davon
WO2011113320A1 (zh) 包含决奈达隆的药物组合物
CA2612288A1 (en) Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
WO2015106963A1 (en) Pharmaceutical composition comprising aripiprazole or salt thereof
KR101799539B1 (ko) 도세탁셀을 포함하는 경구용 고형지질나노입자 조성물
CN117979959A (zh) 药物组合物及其制备方法
WO2010082855A1 (en) Pharmaceutical compositions comprising ziprasidone free base or ziprasidone hydrochloride and the method for their preparation
KR20110029249A (ko) 프란루카스트의 향상된 용해도를 갖는 약학적 조성물
rights are reserved by Kharde et al. Formulation and Evaluation of Fast Disintegrating Tablet of Carvedilol
TW201247246A (en) Dronedarone solid dispersion and its preparation method

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU

NF4A Restoration of lapsed right to a eurasian patent

Designated state(s): RU

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU